Genzyme launches MRD (minimal residual disease) test
This article was originally published in Clinica
Genzyme Genetics has launched a noninvasive test to detect minimal residual disease (MRD) in patients with B-cell chronic lymphocyte leukaemia (B-CLL). MRD refers to undetectable disease in the blood and bone marrow of leukaemia patients in complete remission.
You may also be interested in...
Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.